|Bid||32.27 x 800|
|Ask||34.99 x 1200|
|Day's Range||32.43 - 33.26|
|52 Week Range||28.00 - 37.61|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||237.23|
|Earnings Date||Aug 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.40|
Elanco Animal Health Incorporated (ELAN), today finalized the acquisition of Aratana Therapeutics (PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant®. This transaction allows Elanco to capture the full value of growing product Galliprant®, in which Elanco has had the exclusive rights to develop, manufacture and commercialize since 2016. Additionally, Aratana contributes two additional products to Elanco’s portfolio: Entyce®, the only FDA-approved veterinary therapeutic to stimulate appetite in dogs, and Nocita®, a long-acting local anesthetic that provides up to 72 hours of post-operative pain relief following certain surgeries in dogs and cats.
FRANKFURT/LONDON (Reuters) - Bayer has approached U.S. drug firm Elanco Animal Health to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters. The two companies are working with banks to ensure any merger would secure regulatory approval, the sources said, speaking on condition of anonymity. Bayer has delayed the launch of an auction to private equity funds to clinch a bilateral deal with Elanco, the fourth-largest player in the animal health industry globally, the sources said.
Elanco Animal Health Incorporated (ELAN), announced today a new global R&D collaboration with AgBiome, Inc. to develop nutritional health products for swine. The collaboration further demonstrates Elanco’s commitment to antibiotic stewardship and bringing alternatives to producers’ most difficult challenges.
The size of Elanco Animal Health Incorporated (NYSE:ELAN), a US$12b large-cap, often attracts investors seeking a...
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
A recent SEC filing reveals what led up to the sale of the Leawood animal health company to Elanco last year — and the misperception that Engaged Capital was an interested buyer.
New data published in The American Journal of Occupational Therapy suggests the impact of a service dog may extend beyond the recipient and have positive impacts on family members as well. This study, funded by Elanco Animal Health Incorporated (ELAN) and conducted by Purdue University College of Veterinary Medicine, is the first of its kind using standardized measures to examine the relationship between the human animal bond and psychosocial outcomes among people with service dogs.
GREENFIELD, Ind.-- -- Gross margin improved 190 basis points to 53.0 percent of revenue Earnings per share was $0.09 , or $0.25 Revenue declined 1 percent to $731.1 million; Total and Core Revenue both grew 2 percent at constant currency rates Revenue from Innovation portfolio grew 59 percent, represents 13 percent of total revenue Announced agreement to acquire Aratana Therapeutics and collaboration ...
Elanco Animal Health (ELAN) today announced the appointment of Art A. Garcia, recently retired executive vice president and chief financial officer of Ryder System Inc., to the Board of Directors. The board was established in September 2018 when Elanco became a publicly traded company following its separation from Eli Lilly and Company.
NEW YORK, April 30, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.
Health care stocks were the best sector in the Standard & Poor's 500-stock index in 2018, according to Yardeni Research. The sector's 4.7% gain last year isn't exactly eye-popping. But consider that utilities (+0.5%) were the only sector in the black, and that the index itself lost 6.2% ... and you realize just how impressive health care actually was.As we look ahead to 2019, economic storm clouds appear to be gathering. Although a recession is unlikely in the year ahead, UCLA economists estimate that GDP growth will shrink from 3% in 2018 to 2% in 2019 and finally 1% in 2020.Thus, in the potential absence of a good offense, it makes sense for investors to buy some defense in 2019. The best health care stocks can fit that bill. "Health care is a defensive growth sector that we think should have a growth upturn over the next five years or so," Saira Malik, head of global equities at Nuveen, told Fortune in November.With that in mind, here are 10 health care stocks to buy for 2019. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
NEW YORK, April 29, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Aratana Therapeutics, Inc. (NASDAQ: PETX) on.
Elanco Animal Health (ELAN) will announce its first quarter 2019 financial results on Thursday, May 9, 2019. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance. The conference call will begin at 8:00 a.m. Eastern time.
WILMINGTON, Del., April 29, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Quantenna Communications, Inc. (NYSE: QTNA) regarding possible breaches.
NEW YORK, April 29, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Aratana Therapeutics, Inc..
NEW YORK , April 26, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Aratana Therapeutics, Inc. (NASDAQ: PETX) and its board of directors for breach of fiduciary duty concerning ...
Elanco Animal Health Inc (NYSE: ELAN) announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc (NASDAQ: PETX). The stock-for-stock deal is worth as much as $245 million, Elanco said. The deal would grant Aratana shareholders 0.1481 Elanco shares and one cash contingent value right for each Aratana share, and the shares to be issued represent about 2 percent of outstanding Elanco shares.
First-quarter earnings reports are flooding the wires this week and both the Nasdaq and S&P 500 have attained all-time highs. The space has been hurt by political rhetoric as the 2020 election cycle starts to get in full swing. Let's consider a few biotech names and start on a high note.